Flynn LL, Mitrpant C, Pitout IL, Fletcher S, and Wilton SD, Antisense oligonucleotide mediated terminal intron retention of the SMN2 transcript. Mol Ther Nucleic Acids, 2018. (in press).

Martinovich KM, Shaw NC, Kicic A, Schultz A, Fletcher S, Wilton SD, and Stick SM, The potential of antisense oligonucleotide therapies for inherited childhood lung diseases. Mol Cell Pediatr, 2018. 5(1): p. 3.

Martinovich KM, Shaw NC, Kicic A, Schultz A, Fletcher S, Wilton SD, and Stick SM, The potential of antisense oligonucleotide therapies for inherited childhood lung diseases. Mol Cell Pediatr, 2018. 5(1): p. 3.

Targeted alternative splicing: a common therapeutic platform to treat inherited diseases. Wilton, Fletcher, Zheng, Mastaglia. 2018-2020 $798,165. NHMRC Application 114479.1

Stargardt disease. Chen, de Roach, Hunt and Wilton. 2018-2019 $120,000. Macular Disease Foundation.

Le BT, Adams AM, Fletcher S, Wilton SD, and Veedu RN (2017) Rational design of short locked nucleic acid-modified 2’-O-methyl antisense oligonucleotides for efficient exon-skipping in vitro. Molecular Therapy – Nucleic Acids, 9, 155–161. doi: 10.1016/j.omtn.2017.09.002 [Rank: Q1; Cell Press]

Comprehending the Health Informatics Spectrum: Grappling with System Entropy and Advancing Quality Clinical Research Bellgard MI, Chartres N, Watts GF, Wilton SD, Fletcher S, Hunter A, Snelling T 2017 Front Public Health 5: 224

Rational Design of Short Locked Nucleic Acid-Modified 2′-O-Methyl Antisense Oligonucleotides for Efficient Exon-Skipping In Vitro Le BT, Adams AM, Fletcher S, Wilton SD and Veedu RN 2017 Mol Ther Nucleic Acids 9: 155-161

Rational design of short locked nucleic acid-modified 2’-O-methyl antisense oligonucleotides for efficient exon-skipping in vitro. Le BT, Adams AM, Fletcher S, Wilton SD, and Veedu RN (2017) Molecular Therapy Nucleic Acids, 9, 155–161. doi: 10.1016/j.omtn.2017.09.002